JCOVDEN, suspension for injection vaccine against COVID-19 (ad26.cov2-s [recombinant]) 50 doses
Active ingredients: ADÉNOVIRUS TYPE 26 CODANT POUR LA GLYCOPROTÉINE SPIKE DU SARS-COV-2
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for injection50 dosesintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- JCOVDEN, suspension injectable Vaccin contre la COVID-19 (Ad26.COV2-S [recombinant])
- Pharmaceutical form
- suspension injectable
- Route of administration
- intramusculaire
- Presentation description
- 10 flacons multidoses en verre de 5 doses
- Marketing authorisation holder
- JANSSEN CILAG INTERNATIONAL NV
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 Mar 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64798803CIP73022223CIP133400930222232Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ADÉNOVIRUS TYPE 26 CODANT POUR LA GLYCOPROTÉINE SPIKE DU SARS-COV-2suspension | non inférieur à 8,92 log10 U. Inf. · une dose de 0,5 mL (1 flacon contient 5 doses) | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.